HCPCS J3145: Injection, Testosterone Undecanoate, 1 mg
HCPCS Level II code J3145 represents the injectable medication testosterone undecanoate, 1 mg. As a drug administration code, it matters nationally for outpatient medical billing, hormone therapy management, and payer coverage determinations involving androgen replacement or related therapeutic uses. Accurate coding of this product affects claims processing, medical necessity review, and pharmacy/medical benefit delineation.
Key payers referenced in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides readers with benchmarks for how this HCPCS Level II code is billed across common outpatient sites, summarizes payer coverage considerations, and outlines clinical context for its use as an injectable testosterone therapy. It also highlights relevant policy items that influence reimbursement pathways and claim adjudication.
Readers will learn what the code denotes, where the service is typically provided, which major payers are relevant to billing, and which topics to consult for payer-specific policy language or benefit design. Data not available in the input is noted where applicable.
Customize your policy alerts
Sign up for hcpcs J3145 policy alerts
Get alerted when payer policies referencing J3145 are released or updated.
Monitor payer policy activity
Billing Code Overview
HCPCS Level II code J3145 denotes Injection, testosterone undecanoate, 1 mg. This code represents a billed administration of the specified testosterone formulation as a medication service. The service type is an injectable hormone therapy medication, typically administered as an intramuscular injection.
The typical site of service for billing with this code is outpatient clinical settings where parenteral medications are administered, including physician offices, outpatient clinics, and ambulatory infusion or injection suites.